AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1389512
Drug: High-dose prochlorperazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prochlorperazine 0.8 mg/kg intravenously
Trial: 1389512
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide 2 mg/kg intravenously
Trial: 27383293
Drug: 0.5 g/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg/week IVIG
Trial: 27383293
Drug: 1.0 g/kg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg/week IVIG
Trial: 23252878
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg vortioxetine
Trial: 15472494
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg (titrated to 10 mg after 4 weeks)
Trial: 15472494
Drug: Ramipril 2.5
RxNorm normalized name: ramipril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 2.5 mg (titrated to 5 mg and 10 mg after 1 and 3 weeks)
Trial: 3526534
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) monotherapy without steroids
Trial: 29415846
Drug: Opioid-dependence pharmacotherapy
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-dependence pharmacotherapy (methadone, buprenorphine, oral naltrexone)
Trial: 29415846
Drug: Opioid-dependence pharmacotherapy
RxNorm normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid-dependence pharmacotherapy group
Trial: 29415846
Drug: Outpatient substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient substance abuse treatment without opioid-dependence pharmacotherapy
Trial: 24571282
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text messages for 6 months
Trial: 21110437
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 250-1000 mg ademetionine for 28 days
Trial: 21110437
Drug: Yinzhihuang Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinzhihuang Granule and Compound Glycyrrhizin Injection (control group)
Trial: 12814852
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR (75 or 150 mg/d)
Trial: 12814852
Drug: diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam (15 mg/d)
Trial: 12814852
Drug: venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: venlafaxine XR (75 or 150 mg/d) from verum-sensitive centres
Trial: 1653140
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg sumatriptan (second dose at 1 hour)
Trial: 1653140
Drug: placebo (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (second dose at 1 hour)
Trial: 6411497
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 25 mg/day
Trial: 6411497
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 50 mg/day
Trial: 6411497
Drug: Mesterolone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesterolone (100 mg/day)
Trial: 6411497
Drug: Testosterone rebound
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone rebound therapy (100 or 250 mg on alternate weeks)
Trial: 9386141
Drug: Maxepa 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxepa 5 capsules BID for 3 months
Trial: 3219274
Drug: Prednisolone 5
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 mg bd
Trial: 3219274
Drug: Primary endocrine
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary endocrine treatment alone (PET)
Trial: 23234810
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 20 mg/d (early-treatment)
Trial: 23234810
Drug: Placebo (delayed-treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (delayed-treatment)
Trial: 15333721
Drug: DHA-enriched baby
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched baby food (115 mg DHA/100 g food, 1 jar (113 g)/d)
Trial: 15333721
Drug: Control baby
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control baby food (0 mg DHA)
Trial: 8083711
Drug: Split hyperfractionated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split hyperfractionated radiotherapy (2.0 Gy/d for 30 to 40 days, total 48 Gy to 60 Gy) and chemotherapy (cisplatin 80 to 100 mg/m2 and fluorouracil 1,000 mg/m2 for 3 to 4 days, +/- vindesine 8 mg/m2 for two cycles)
Trial: 8083711
Drug: Split hyperfractionated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Split hyperfractionated radiotherapy and chemotherapy
Trial: 2809258
Drug: Purified acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified acellular pertussis vaccine (12.5 micrograms LPF and 12.5 micrograms FHA)
Trial: 1108565
Drug: Heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 5,000 i.u. every 12 hours
Trial: 31661012
Drug: Biological dressing
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological dressing composed of fetal fibroblasts and keratinocytes
Trial: 22123381
Drug: Levocetirizine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine, 5 mg daily for 1 week
Trial: 22123381
Drug: Cetirizine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine, 10 mg daily for 1 week
Trial: 22123381
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill for 1 week
Trial: 16691131
Drug: ICP-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-directed therapy in patients with severe TBI (n = 24)
Trial: 15285121
Drug: Different descriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different descriptions of winning conditions (e.g., 'if one or the other but not both picks a red card' vs. 'if one or the other but not both picks a black card')
Trial: 8276048
Drug: Ramipril 1.25
RxNorm normalized name: ramipril 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 1.25 mg
Trial: 3440636
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ketanserin and hydrochlorothiazide
Trial: 25064437
Drug: Peginterferon lambda-1a
RxNorm normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon lambda-1a (Lambda) 120/180/240 μg
Trial: 25064437
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a (alfa) 180 μg
Trial: 18762591
Drug: Family-focused treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-focused treatment for adolescents (FFT-A) and protocol pharmacotherapy (n = 30)
Trial: 18762591
Drug: Enhanced care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care (EC) and protocol pharmacotherapy (n = 28)
Trial: 31518717
Drug: Magnetic Sphincter
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic Sphincter Augmentation (MSA)
Trial: 31263057
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (325 mg/day)
Trial: 21610123
Drug: diacerein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein (50 mg once daily for the first 15 days and twice daily for 45 additional days)
Trial: 19492999
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of green tea
Trial: 19492999
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of white tea
Trial: 16541308
Drug: Sentinel lymph
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel lymph node biopsy (SLNB) using a combination of radiopharmaceutical 99mTc‐albumin colloid and Patent Blue V dye
Trial: 16541308
Drug: Sentinel lymph
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sentinel lymph node biopsy (SLNB) using a combination of blue dye and isotope
Trial: 21838089
Drug: Tretinoin gel
RxNorm normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin gel microsphere 0.1%
Trial: 1644335
Drug: 4-aminosalicylic acid
RxNorm normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-aminosalicylic acid (4-ASA) 2 g enemas
Trial: 1644335
Drug: Prednisolone 20
RxNorm normalized name: prednisolone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 20 mg enemas
Trial: 6092557
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (40 patients)
Trial: 6092557
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment with bronchodilators
Trial: 6092557
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (with or without bronchodilators)
Trial: 29288501
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (10 grams of iodized salt daily)
Trial: 24385534
Drug: Deferasirox (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (target dose 40 mg/kg per day)
Trial: 24385534
Drug: Deferoxamine (50‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferoxamine (50‐60 mg/kg per day for 5‐7 days/week)
Trial: 20456627
Drug: female arousal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: female arousal gel
Trial: 16336447
Drug: 0.09 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09 mg/kg midazolam
Trial: 12201618
Drug: Mix25 (25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mix25 (25% insulin lispro and 75% NPL)
Trial: 30293464
Drug: Internally cooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internally cooled wet (ICW) electrodes with saline infusion
Trial: 29753033
Drug: Nemolizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.1 mg/kg Q4W
Trial: 29753033
Drug: Nemolizumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.5 mg/kg Q4W
Trial: 29753033
Drug: Nemolizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 2.0 mg/kg Q4W
Trial: 29753033
Drug: Nemolizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 2.0 mg/kg Q8W
Trial: 19961017
Drug: TIVA (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (total intravenous anesthesia)
Trial: 17980419
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (FO) supplementation with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mug of methyl‐tetra‐hydrofolic acid
Trial: 31929122
Drug: Gocovri (amantadine)
RxNorm normalized name: Gocovri
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gocovri (amantadine) 274 mg once daily at bedtime
Trial: 31778629
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (1.5 g every 6 hours)
Trial: 29052559
Drug: Niaoduqing particles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks
Trial: 29052559
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered using the same methods for 24 weeks
Trial: 26174334
Drug: Psychoeducation (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation (6 weekly sessions)
Trial: 26174334
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise (6 weekly sessions)
Trial: 19137409
Drug: Bicarbonate (Bi)
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate (Bi) infusion in dextrose water
Trial: 19137409
Drug: Oral acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acetazolamide (AZ) with normal saline (NLS)
Trial: 19137409
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NLS) infusion alone
Trial: 17507633
Drug: Adjuvant taxane-anthracycline-containing
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab (Herceptin)
Trial: 9595988
Drug: OPC-14117 60
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-14117 60 mg/d
Trial: 9595988
Drug: OPC-14117 120
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-14117 120 mg/d
Trial: 9595988
Drug: OPC-14117 240
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC-14117 240 mg/d
Trial: 2539017
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 to 40 mg daily)
Trial: 2539017
Drug: Atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50 to 100 mg daily)
Trial: 23537617
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (goserelin) for 3 months (Group 1)
Trial: 19691907
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg quetiapine XR
Trial: 19691907
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg quetiapine XR
Trial: 18624596
Drug: Medication, reducing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication, reducing salty foods, and losing weight
Trial: 15780844
Drug: D-serine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine (30 mg/kg/day)
Trial: 11870242
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (0.25 mg, 0.5 mg, 1 mg at three-month intervals; 4 mg as a single dose; 2 mg doses six months apart)
Trial: 10195357
Drug: Cetirizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (20 mg)
Trial: 10195357
Drug: Dimethindene (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethindene (4 mg)
Trial: 10195357
Drug: H1-antagonists (Cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1-antagonists (Cetirizine and Dimethindene)
Trial: 7850984
Drug: 0.8 mg/h
RxNorm normalized name: nitroglycerin 0.8 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg/h transdermal nitroglycerin
Trial: 1691125
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy only
Trial: 1691125
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy followed by endoscopic intubation
Trial: 7361087
Drug: Diflunisal (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500-750 mg daily)
Trial: 7361087
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (2000-3000 mg daily)
Trial: 25481453
Drug: 4-week taper
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week taper condition (N=22)
Trial: 17239942
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml Patent Blue diluted with 8 ml NaCl 0.9%
Trial: 17239942
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml Patent Blue (standard labelling volume)
Trial: 9714946
Drug: Danger ideation
RxNorm normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Danger ideation reduction therapy (DIRT)
Trial: 7992096
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (CVD) plus interleukin-2 (IL-2) and interferon-alfa (IFN-alpha)
Trial: 7992096
Drug: Biotherapy (IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered immediately after CVD
Trial: 7992096
Drug: Biotherapy (IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered in a sandwich of biotherapy/CVD/biotherapy
Trial: 7992096
Drug: Biotherapy (IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotherapy (IL-2 plus IFN-alpha) administered concurrently with CVD
Trial: 27015572
Drug: Subtenon triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subtenon triamcinolone acetonide (TA) injection
Trial: 25640290
Drug: Immediate-release tapentadol
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tapentadol
Trial: 21209411
Drug: AFQ056 (mGluR5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFQ056 (mGluR5 antagonist)
Trial: 17848936
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (160 IU/day, administered four times a day for 8 weeks)
Trial: 16403776
Drug: ExGLU (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ExGLU (75 g of glucose in 250 ml of water)
Trial: 9437565
Drug: Low electrical
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low electrical dosage relative to seizure threshold
Trial: 9437565
Drug: High electrical
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High electrical dosage relative to seizure threshold
Trial: 8267194
Drug: Low-dose naloxone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naloxone (0.5 microgram.kg‐1.min‐1)
Trial: 8267194
Drug: High-dose naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naloxone (11.5 micrograms/kg bolus followed by 5 micrograms.kg‐1.min‐1 infusion)
Trial: 3545282
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg danazol
Trial: 3545282
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg danazol
Trial: 3545282
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg danazol
Trial: 29655497
Drug: Intraosseous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous regional administration (IORA) of 500 mg vancomycin into the tibia
Trial: 29655497
Drug: Systemic intravenous
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic intravenous (IV) administration of 15 mg/kg (maximum of 2 g) vancomycin
Trial: 26651278
Drug: Helmetless-tackling intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Helmetless-tackling intervention (5-minute tackling drill without helmets and shoulder pads, twice per week in preseason and once per week during the season)
Trial: 11332932
Drug: Bolus gavage
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus gavage feeding with milk (12 ml kg(‐1) d(‐1) increments, 12 meals per day)
Trial: 3198936
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated H1N1 reassortant vaccine
Trial: 3198936
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated H3N2 reassortant vaccine
Trial: 3198936
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated virus vaccine